Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index rising 1.8% and the Health Care Select Sector SPDR Fund (XLV) adding 1.5%.
The iShares Biotechnology ETF (IBB) climbed 1.5%.
In corporate news, DexCom (DXCM) shares jumped past 16%. The company late Thursday maintained its full-year revenue guidance after delivering a Q1 sales beat.
BrightSpring Health Services (BTSG) shares surged more than 16% after it reported Q1 adjusted EPS and revenue above analyst expectations and raised its 2025 revenue guidance.
Cytokinetics (CYTK) shares fell 12% after the US Food and Drug Administration extended the Prescription Drug User Fee Act action date to Dec. 26 for aficamten in obstructive hypertrophic cardiomyopathy in the previous day.
Novo Nordisk (NVO) shares popped 5.7% after Health Canada accepted for review a supplemental new drug submission for semaglutide 2.4 mg as a once weekly treatment for people with metabolic dysfunction-associated steatohepatitis.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。